Axonics® system for treatment of overactive bladder syndrome and urinary urgency incontinence
暂无分享,去创建一个
[1] B. Blok,et al. Two‐year outcomes of the ARTISAN‐SNM study for the treatment of urinary urgency incontinence using the Axonics rechargeable sacral neuromodulation system , 2021, Neurourology and urodynamics.
[2] B. Blok,et al. One‐year outcomes of the ARTISAN‐SNM study with the Axonics System for the treatment of urinary urgency incontinence , 2020, Neurourology and urodynamics.
[3] J. Hippisley-Cox,et al. Anticholinergic Drug Exposure and the Risk of Dementia , 2019, JAMA internal medicine.
[4] B. Blok,et al. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12‐month results from the RELAX‐OAB study , 2019, Neurourology and urodynamics.
[5] H. Goldman,et al. Can Lumbosacral Magnetic Resonance Imaging be Performed Safely in Patients with a Sacral Neuromodulation Device? An In Vivo Prospective Study , 2018, The Journal of urology.
[6] D. Myers,et al. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. , 2018, European urology.
[7] K. Matzel,et al. International Continence Society best practice statement for use of sacral neuromodulation , 2018, Neurourology and urodynamics.
[8] D. Elterman,et al. The novel Axonics® rechargeable sacral neuromodulation system: Procedural and technical impressions from an initial North American experience , 2018, Neurourology and urodynamics.
[9] C. Comiter,et al. Five‐Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation , 2018, The Journal of urology.
[10] F. Burkhard,et al. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. , 2018, European urology.
[11] H. Goldman,et al. Removal of Sacral Nerve Stimulation Devices for Magnetic Resonance Imaging: What Happens Next? , 2017, Neuromodulation : journal of the International Neuromodulation Society.
[12] M. D. Mason,et al. Prospective Evaluation of Sacral Neuromodulation in Children: Outcomes and Urodynamic Predictors of Success. , 2016, The Journal of urology.
[13] M. Barber,et al. Erratum to: An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP) , 2016, International Urogynecology Journal.
[14] M. Barber,et al. An International Urogynecological Association (IUGA) / International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP) , 2016, International Urogynecology Journal.
[15] M. McPheeters,et al. Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women: A Systematic Review and Meta-analysis , 2015, Obstetrics and gynecology.
[16] M. Faraday,et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. , 2015, The Journal of urology.
[17] Stephanie A. Jacobs,et al. Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet , 2014, Neurourology and urodynamics.
[18] Y. Reinberg,et al. Sacral neuromodulation for the dysfunctional elimination syndrome: a 10-year single-center experience with 105 consecutive children. , 2013, Urology.
[19] C. Thompson,et al. The impact of OAB on physical activity in the United States: results from OAB-POLL. , 2013, Urology.
[20] C. Thompson,et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB‐POLL , 2013, Neurourology and urodynamics.
[21] K. Coyne,et al. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. , 2012, Urology.
[22] K. Coyne,et al. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. , 2012, Urology.
[23] B. Blok,et al. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. , 2011, The Journal of urology.
[24] T. Griebling. Sacral nerve stimulation in the elderly , 2010, International Urogynecology Journal.
[25] J. Benner,et al. Patient‐reported reasons for discontinuing overactive bladder medication , 2010, BJU international.
[26] S. Wexner,et al. Infection Rates in a Large Investigational Trial of Sacral Nerve Stimulation for Fecal Incontinence , 2010, Journal of Gastrointestinal Surgery.
[27] Jim C Hu,et al. Economic costs of overactive bladder in the United States. , 2010, Urology.
[28] A. Stenzl,et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury , 2010, Annals of neurology.
[29] Jennifer M Wu,et al. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review , 2010, Neurourology and urodynamics.
[30] Jim C Hu,et al. Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community‐based sample , 2009, BJU international.
[31] F. Klein,et al. Sacral nerve stimulation for refractory overactive bladder in the elderly population. , 2009, The Journal of urology.
[32] F. Klein,et al. Incidence and predictors of complications with sacral neuromodulation. , 2008, Urology.
[33] M. Spinelli,et al. Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety. , 2008, European urology.
[34] M. Elhilali,et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. , 2007, The Journal of urology.
[35] R. Dmochowski,et al. Impact of overactive bladder on women in the United States:results of a national survey , 2007, Current medical research and opinion.
[36] K. Coyne,et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. , 2006, European urology.
[37] Dick J Veltman,et al. Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators , 2006, BJU international.
[38] Craig A. Smith,et al. Preliminary results of sacral neuromodulation in 23 children. , 2006, The Journal of urology.
[39] J. R. Ruud Bosch,et al. Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding. , 2006, The Journal of urology.
[40] H. Birnbaum,et al. Employees With Overactive Bladder: Work Loss Burden , 2005, Journal of occupational and environmental medicine.
[41] M. Chancellor,et al. How sacral nerve stimulation neuromodulation works. , 2005, The Urologic clinics of North America.
[42] M. Fall,et al. Sacral nerve stimulation for refractory urge symptoms in elderly patients , 2004, Scandinavian journal of urology and nephrology.
[43] W. Stewart,et al. Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.
[44] G. Webster,et al. Sacral neuromodulation in an older, urge-incontinent population. , 2002, American journal of obstetrics and gynecology.
[45] R A Janknegt,et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. , 1999, The Journal of urology.